Clopidogrel Protects Endothelium by Hindering TNFα-Induced VCAM-1 Expression through CaMKKβ/AMPK/Nrf2 Pathway

Area of Science:

• Endocrinology
• Molecular Biology
• Pharmacology

Background:

• Oxidative stress is a key factor in inflammatory diseases like diabetes and atherosclerosis.
• Clopidogrel, an antiplatelet drug, exhibits anti-inflammatory and antioxidant properties.
• Understanding clopidogrel's molecular mechanisms in inflammation is crucial for therapeutic development.

Purpose of the Study:

• To investigate the anti-inflammatory effects of clopidogrel in human aortic endothelial cells.
• To elucidate the molecular pathways involved in clopidogrel's anti-inflammatory actions.

Main Methods:

• Human aortic endothelial cells were treated with clopidogrel and TNFα.
• Reactive oxygen species (ROS) generation, heme oxygenase 1 (HO-1) expression and activity, and glutathione (GSH) levels were measured.
• Cell adhesion assays were performed using HL-60 cells.
• Western blotting and gene silencing (shRNA) were used to investigate signaling pathways (CaMKKβ/AMPK, Nrf2).

Main Results:

• Clopidogrel reduced TNFα-induced ROS generation and increased cellular GSH levels.
• Clopidogrel time-dependently induced HO-1 expression and activity.
• Silencing HO-1 blocked clopidogrel's suppression of TNFα-induced HL-60 cell adhesion.
• Clopidogrel inhibited TNFα-induced VCAM-1 expression and HL-60 cell adhesion.
• The CaMKKβ/AMPK/Nrf2 pathway was implicated in HO-1 induction by clopidogrel.

Conclusions:

• Clopidogrel exerts anti-inflammatory effects by reducing oxidative stress and inhibiting endothelial cell activation.
• Clopidogrel's mechanism involves the induction of HO-1 via the CaMKKβ/AMPK/Nrf2 pathway.
• These findings highlight clopidogrel's potential beyond its antiplatelet activity in managing inflammatory conditions.